Jump to:
Poolbeg Pharma PLC Fundamentals
| Company Name | Poolbeg Pharma PLC | Last Updated | 2024-12-19 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 500.000 m | Market Cap | £35.56 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.01 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
|---|
| Asset Equity Ratio | 1.0451 | Cash Equity Ratio | 0.8082 |
|---|
| Quick Ratio | 19.2050 | Current Ratio | 19.61 |
|---|
| Price To Book Value | 2.8835 | ROCE | 0 |
|---|
Poolbeg Pharma PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Poolbeg Pharma PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|
| Tangible Assets | 0 | 0 | 0 |
| Intangible Assets | £1.93 m | £2.13 m | £1.56 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £1.93 m | £2.13 m | £1.56 m |
| Stocks | 0 | 0 | 0 |
| Debtors | £700,000.00 | £878,000.00 | £457,000.00 |
| Cash & Equivalents | £12.17 m | £16.19 m | £20.95 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £15.43 m | £19.29 m | £23.02 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|
| Creditors within 1 year | £986,000.00 | £966,000.00 | £438,000.00 |
| Creditors after 1 year | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £986,000.00 | £966,000.00 | £438,000.00 |
| Net assets | £14.44 m | £18.32 m | £22.58 m |
| Equity | 2023 | 2022 | 2021 |
|---|
| Called up share capital | £100,000.00 | £100,000.00 | £100,000.00 |
| Share Premium | £23.10 m | £23.10 m | £23.10 m |
| Profit / Loss | -£4.50 m | -£4.78 m | -£2.34 m |
| Other Equity | £14.44 m | £18.32 m | £22.58 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £14.44 m | £18.32 m | £22.58 m |
| Ratios | 2023 | 2022 | 2021 |
|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | 1.0451 | 1.0451 | 1.0451 |
| Cash / Equity | 0.8082 | 0.8082 | 0.8082 |
| EPS | -£0.01 | -£0.01 | -£0.01 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|
| Cash from operating activities | -£4.38 m | -£4.37 m | -£2.15 m |
| Cashflow before financing | -£4.38 m | -£4.37 m | £21.03 m |
| Increase in Cash | -£4.02 m | -£4.76 m | £20.95 m |
| Income | 2023 | 2022 | 2021 |
|---|
| Turnover | 0 | 0 | 0 |
| Cost of sales | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Profit | -£5.04 m | -£4.99 m | -£2.34 m |
| Pre-Tax profit | -£4.50 m | -£4.78 m | -£2.34 m |
Poolbeg Pharma PLC Company Background
| Sector | Healthcare |
|---|
| Activities | Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire. |
|---|
| Latest Interim Date | 18 Sep 2024 |
|---|
| Latest Fiscal Year End Date | 30 Apr 2024 |
|---|
Poolbeg Pharma PLC Directors
| Appointed | Name | Position |
|---|
| 2023-11-30 | Mr. Patrick Joseph Ashe | Non-Executive Director |
| 2024-05-09 | Mr. Cathal Martin Friel | Executive Director,Chairman |
| 2024-05-09 | Professor Brendan Buckley | Non-Executive Director |
| 2024-05-09 | Dr. Jeremy Skillington | Executive Director,Chief Executive Officer |
| 2024-05-09 | Mr. Ian O'Connell | Executive Director,Chief Financial Officer |
Poolbeg Pharma PLC Contact Details
Poolbeg Pharma PLC Advisors
